medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2006, Número 4

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2006; 4 (4)


Micosis fungoides: biología y terapéutica

González-Ramírez RA, Ocampo-Candiani J, Méndez-Olvera N, Gómez-Flores M

Idioma: Español
Referencias bibliográficas: 32
Paginas: 278-287
Archivo PDF: 443.40 Kb.


RESUMEN

La micosis fungoides representa la variante más frecuente de linfomas cutáneos de células T, es de curso indolente y en etapas finales puede tener diseminación extracutánea. Afecta principalmente a hombres, predominando en la raza afroamericana. Se han relacionado múltiples factores en su etiopatogenia: infecciones virales, químicos, exposición solar, tabaquismo, entre otros. Los linfocitos T y algunas moléculas de adhesión tienen un papel crucial en el desarrollo de este padecimiento, considerado inicialmente inflamatorio crónico, con potencial malignización. Evoluciona en tres etapas clínicas: de parche, placa, tumoral y finalmente síndrome Sézary, esta última con la presencia de células malignas en sangre periférica. El tratamiento depende del estadio clínico y se ha ampliado en los últimos años.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Epstein EH, Zackheim HS, McNutt NS. “Mycosis fungoides and variants”. En: Demis DJ. Clinical Dermatology. 1th Edition. 17 reimp. J B Lippincot Company. Vol 4 Chapter 20-11, 1990

  2. Sézary A, Bouvrain Y. Erythrodermie avec presence de cellules montrueuses dans le derme et dans le lang circulant. Bull Soc Fr Dermatol Syphiligr 1938; 45: 254-260

  3. Wilson LD, Kacinski BM, Edelson RL, Heald PW. “Cutaneous TCell Lymphomas”. En: DeVita Jr VT, Hellman S, Rosemberg SA. Cancer: Principles and Practice of Oncology. 5th Edition. Lippincot-Raven Contributors. Chapter 44.4; 1997: 2220-2230

  4. Whittemore AS, Holly EA, Lee IM, et al. Mycosis Fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst 1989; 81: 1560-1567

  5. Morales-Suárez-Varela MM, Olsen J, Johansen P, et al. Occupational risk factors for mycosis fungoides: A European multicenter case-control study. J Occup Environ Med 2004; 46: 205-211

  6. Góngora Biachi RA, González-Martínez P, Puerto-Manzano F, Yamaguchi K, Nishimura Y, Takatsuki K. Micosis fungoide asociada al virus linfotrópico de células T humanas en Yucatán. Rev Invest Clin 1991; 43: 111

  7. Pancake BA, Zucker-Franklin D, Coutavas EE. The Cutaneous T Cell Lymphoma, Mycosis Fungoides, Is a Human T Cell Lymphotrophic Virusassociated Disease: a study of 5 patients. J Clin Invest 1995; 95: 547-554

  8. Robert C. Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. NEJM 1999; 341 (24): 1827-1828

  9. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. NEJM 2004; 350 (19): 1978-1988

  10. Rossete C. Karin M. Ultraviolet light and osmotic stress: activation of the INK cascade through multiple growth factor and cytokine receptors. Science 1996; 274: 1194-1197

  11. Suchin KR, Cassin M, Gottleib SL et al. Increased interleukin 5 production in eosinophilic Sézary syndrome: Regulation by interferon alfa and interleukin

  12. J Am Acad Dermatol 2001; 44: 28-32 12. Kim EJ, Hess S, Richardson SK. Inmunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115 (4): 798-812

  13. EntrezPubmed: http://www.ncbi.nlm.nih.gov/nationalcenterforbiotechnologyinformation. com.

  14. Scarisbrick JJ, Mitchell TJ, Calonje E et al. Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 2003; 121: 894-901

  15. Navas IC, Ortiz-Romero PL, Villuendas R y cols. P16INK4a gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol 2000; 156: 1565-1572

  16. Van Doorn R, Zoutman WH, Dijkman R et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005; 23: 3886-3896

  17. Ni X, Hazarika P, Zhang C et al. Fas ligand expresión by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 2001; 7: 2682-2692

  18. Strutton G. “Cutaneous infiltrates-lymphomatous and leukemic”. En: Weedon D. Skin Pathology. 2a ed. Churchill Livingstone 2002. Chapter 41: 1104-1111

  19. Sokolowska-Wojdylo M, Wenzel J, Gaffal E. Circulating clonal CLA4+ T cells in Sézary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol 2005; 152: 258-264

  20. 20.Bunn PA, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63: 725-728

  21. Kashani-Sabet M, McMillan A, Zackheim HS. A modified staging classification for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001; 45: 700-706

  22. Vonderheid EC, Bernengo MG, Burg G et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95-106

  23. Massone C, Kodama K, Kerl H, Cerroni L. Histopathologic features of early (patch) lesions of Mycosis Fungoides: a morphology study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 2005; 29 (4): 550-560

  24. Breneman DL, Raju US, Breneman JC et al. Lymph node grading for staging of mycosis fungoides may benefit from examination of multiple excised lymph nodes. J Am Acad Dermatol 2003; 48 (5): 702-706

  25. Lee BN, Duvic M, Tang CHK et al. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol 1999; 6 (1): 79-84

  26. 26.Bergman R, Faclieru D, Sahar D et al. Immunophenotyping and T-cell receptor Á gene rearrangement analysis as an adjunt to the histopathologic diagnosis of mycosis fungoides. J Am Acad Dermatol 1998; 39: 554-559

  27. Dearden CE, Foss FM. Peripheral T-cell lymphomas: diagnosis and management. Hematol Oncol Clin N Am 2003; 17: 1351-1366

  28. Querfeld C, Rosen ST, Guitart J, Kuzel TM. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol 2005; 12: 273-278 29.Kuzel TM, Junghans R, Foss FM. Novel agents for cutaneous T-cell lymphoma. Hematol Oncol Clin N Am 2003; 17: 1459-1466

  29. 30.Oyama Y, Guitart J, Kuzel TM, Burt RK, Rosen ST. High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma. Hematol Oncol Clin N Am 2003; 17: 1475-1483

  30. Herbert KE, Spencer A, Grigg A et al. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplantation 2004; 34: 521-525

  31. Brightman L, Demierre MF. Thalidomide in mycosis fungoides. Letters. J Am Acad Dermatol 2005; 52 (6): 1100-1101

  32. Klemke CD, Mansmann U, Poenitz N et al. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol 2005; 153: 118-124 Volumen




2020     |     www.medigraphic.com